The patient-derived organoids, though, couldn't predict response to a 5-fluorouracil plus oxaliplatin regimen, underscoring more research is needed before clinical use.
The company has collected initial evidence for an algorithmic method to predict immunotherapy response, and is studying its technology in treatment monitoring.
